Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBITDA Margin (2021 - 2025)

Krystal Biotech's EBITDA Margin history spans 4 years, with the latest figure at 48.03% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1.0% year-over-year to 48.03%; the TTM value through Dec 2025 reached 52.98%, up 2258.0%, while the annual FY2025 figure was 52.98%, 2258.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 48.03% at Krystal Biotech, down from 81.09% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1059.99% in Q1 2021 and bottomed at 0.01% in Q1 2024.
  • The 4-year median for EBITDA Margin is 41.17% (2025), against an average of 212.8%.
  • The largest annual shift saw EBITDA Margin tumbled -90706bps in 2024 before it surged 4611bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 1059.99% in 2021, then crashed by -98bps to 23.05% in 2023, then soared by 108bps to 48.04% in 2024, then fell by 0bps to 48.03% in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EBITDA Margin are 48.03% (Q4 2025), 81.09% (Q3 2025), and 40.73% (Q2 2025).